Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Common Equity: 2019-2025

Historic Common Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $315.3 million.

  • Allogene Therapeutics' Common Equity fell 32.00% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.3 million, marking a year-over-year decrease of 32.00%. This contributed to the annual value of $422.2 million for FY2024, which is 17.58% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Common Equity is $315.3 million, which was down 8.48% from $344.6 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Common Equity ranged from a high of $1.1 billion in Q1 2021 and a low of $315.3 million during Q3 2025.
  • In the last 3 years, Allogene Therapeutics' Common Equity had a median value of $463.7 million in 2024 and averaged $474.0 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 76.38% in 2021, then crashed by 33.10% in 2025.
  • Allogene Therapeutics' Common Equity (Quarterly) stood at $925.2 million in 2021, then dropped by 27.92% to $666.9 million in 2022, then decreased by 23.19% to $512.2 million in 2023, then dropped by 17.58% to $422.2 million in 2024, then slumped by 32.00% to $315.3 million in 2025.
  • Its last three reported values are $315.3 million in Q3 2025, $344.6 million for Q2 2025, and $385.4 million during Q1 2025.